Webinar

Navigating Scalability and Consistency in the Allogeneic Supply Chain

Watch this on-demand webinar for an in-depth discussion on these questions and more. You’ll walk away with insights on navigating the scalability of donor starting material as the allogeneic cell therapy industry grows. PANELISTS Abby Waters, PhD Senior Manager, Solutions Owner Be The Match BioTherapies Dean A. Lee, MD, PhD Physician, Hematology and Oncology Director…

Webinar

International Differences in Cellular Starting Material Quality and Regulatory Requirements

Navigating international regulations for cellular starting material is complex. This is particularly true because the rapid advancement of the industry sometimes precedes regulatory guidance. When you’re procuring cellular starting material or distributing a cell or gene therapy product across international borders, you must consider the country or regional requirements at play and where they diverge.…

BioTherapies White Paper

Best practices along the allogeneic product collection pathway

Considerations for developing scalable and efficient collection network processes The decisions you make when selecting apheresis centers to collect source material for your cell or gene therapy impact your ability to efficiently scale your processes. When your processes and protocols differ from those at an apheresis center, delays can occur. Following best practices can help.…

Webinar

Considerations for Developing Scalable and Efficient Collection Network Processes

On-demand webinar offers actionable insights as you develop your protocols. Many crucial considerations impact a cell and gene therapy developer’s apheresis center selection strategy and ability to efficiently scale processes. When collection processes or protocols differ from those in place at a center, there are likely implications for training, forms and standard operating procedures. This…

BioTherapies White Paper

6 Considerations When Evaluating Cell Sourcing Partners

Sourcing your starting material from healthy, high-quality donors matters when you are manufacturing an allogeneic cell therapy. Any misstep can mean delays in your therapy’s development. Keep these key considerations top of mind as you evaluate whether potential partners have the experience, expertise and relationships required to identify, source and collect your allogeneic donors and…